GREG SIECZKIEWICZ

Greg Sieczkiewicz is a distinguished Managing Partner at MPM Capital, a premier investment firm dedicated to building and investing in groundbreaking biotechnology companies. With a profound commitment to advancing human health, Sieczkiewicz plays a pivotal role in identifying and nurturing innovative life science ventures from their inception.

As a Managing Partner, Greg Sieczkiewicz's primary focus at MPM Capital is on company creation and early-stage investments within the biotechnology sector. He is instrumental in the strategic formation and development of new companies, often working closely with scientific founders to translate cutting-edge research into viable therapeutic platforms. His investment thesis centers on disruptive technologies and novel approaches to drug discovery and development, aiming to address significant unmet medical needs. He champions ventures that promise to revolutionize patient care through scientific breakthroughs.

Sieczkiewicz brings a wealth of experience and a unique blend of legal and business acumen to his role. Before joining MPM Capital in 2014, he held critical leadership positions at several highly successful biotechnology companies. Notably, he served as the founding Chief Legal Officer and Secretary at Moderna Therapeutics, where he was instrumental in the company's early growth and intellectual property strategy. Prior to Moderna, he held similar founding Chief Legal Officer roles at Alnylam Pharmaceuticals and Vertex Pharmaceuticals, contributing significantly to their respective journeys in drug development and commercialization. His extensive background in intellectual property, corporate law, and strategic transactions has equipped him with an unparalleled understanding of the complexities involved in building and scaling biotech companies. He earned his Juris Doctor from the University of Pennsylvania Law School and a Bachelor of Science in Chemistry from the University of Massachusetts Amherst.

Through his work at MPM Capital, Greg Sieczkiewicz has been deeply involved in the creation and growth of numerous portfolio companies. While specific "investments" in the traditional sense are often a collective effort at MPM, his expertise is central to the firm's strategy of incubating and launching new entities. His contributions are vital to companies focused on areas like gene editing, RNA therapeutics, and cell therapy, helping to shape the future of medicine. His strategic guidance helps transform scientific discoveries into impactful patient solutions, solidifying his reputation as a key figure in the biotech investment landscape.